ArticleAMB Express2025
Dissecting the role of gut microbiota heterogeneity in the onset of chronic lung diseases.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Evidence from observational studies and clinical trials has reported that gut microbiota (GM) was associated with chronic lung diseases (CLDs). However, the causal relationships between GM and CLDs have yet to be fully ascertained. The Mendelian randomization (MR) based causal analysis was performed using the genome-wide association study (GWAS) summary statistics from the MiBioGen and FinnGen consortium. GM served as exposure, and CLDs were taken for outcomes. Inverse variance weighted, MR-Egger, and weighted median methods were utilized to examine the causal association between GM and CLDs. The sensitivity analyses were then conducted to validate the robustness of the results. Further, the reverse MR analysis was performed to evaluate the possibility of reverse causation. Finally, the in-silico in-situ microbiota resequencing (ISSMR) of high-throughput sequencing data was utilized as a supplement to dissect the role of microbiota spatial distribution disturbance on the onset of idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). This study revealed that GM had causal associations with CLDs. Conversely, reverse MR analysis suggested that the presence of COPD and IPF may causally influence the abundance of specific GM. And ISSMR further provided clues to the interaction of intra-tissue as well as gut microbe disturbance in IPF and COPD from synergistic or independent perspectives. In short, the MR analysis revealed a causal relationship between GM and CLDs from a host genetic perspective, and ISSMR extended the host-microbe regulatory modality from a microbe genetic perspective, thus together providing novel insights into the gut microbiota-mediated development mechanism of CLDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.